Immunogenicity issues in drug development

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 165-172

  Swanson, Steven J ^a  

^a AMGEN INC   (United States)

Author keywords

Biacore; ELISA; Immunogenicity; Neutralizing antibody

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY;

ANALYTIC METHOD; ANTIBODY AFFINITY; ANTIBODY DETECTION; BIOSENSOR; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONFERENCE PAPER; DRUG DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOIMMUNOPRECIPITATION;

EID: 33747591028     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600908852     Document Type: Conference Paper

References (17)

1. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475.
2. Cook-Bruns, N. 2001. Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology 61:58-66.
3. Hanley, J. P., and Haydon, G. H. 1998. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leukem. Lymph. 29:257-268.
4. Holmes, F. A., O'Shaughnessy, J. A., Vukelja, S., Jones, S. E., Shogan, J., Savin, M., Glaspy, J., Moore, M., Meza, L., Wiznitzer, I., Neumann, T. A., Hill, L. R., Liang, B. C. 2002. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 20:727-731.
5. Koren, E., Zuckerman, L. A., and Mire-Sluis, A. R. 2002. Immune responses to therapeutic proteins in humans-Clinical significance, assessment and prediction. Curr. Pharm. Biotech. 3:349-360.
6. Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., and Albrecht, J. K. 2001. Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
7. Mason, S., La, S., Mytych, D., Swanson, S. J., and Ferbas, J. 2003. Validation of the BIAcore 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr. Med. Res. Opin. 19:651-659.
8. Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S. J., Taniguchi, G., Wierda, D., and Zuckerman, L. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immun. Meth. 289:1-16.
9. Pierce Biotechnology, Inc. Binding characteristics of antibody-binding proteins: Protein A, Protein G, Protein A/G and Protein L. Available at: http://www.piercenet.com/files/TR0034dh4-Ab-binding-proteins.pdf.) Accessed on July 7th, 2006.
10. Porter, S. 2001. Human immune response to recombinant human proteins. J. Pharm. Sci. 90:1-11.
11. Rosenberg, M., Kingma, W., Fitzpatrick, M. A., and Richards, S. M. 1999. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081-2088.
12. Schellekens, H. 2003. Immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 18:1257-1259.
13. Swanson, S. J. 2005. Characterization of an immune response. In: State of the Art Analytical Methods for the Characterization of Biological Proteins and Assessment of Comparability. Vol. 122, ed. A. R. Mire-Sluis. Dev. Biol (Basel). Basel: Karger, pp. 95-101.
14. Swanson, S. J., Jacobs S. J., Mytych, D., Shah C, Indelicato, S. R., and Bordens R. W. 1999. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. In: Biological Characterization and Assay of Cytokines and Growth Factors. Vol. 97, eds. F. Brown and A. R. Mire-Sluis. Dev Biol Stand. Basel: Karger, pp. 135-147.
15. Swanson, S. J., Mytych, D. T., and Ferbas, J. 2002. Use of biosensors to monitor the immune response. Devel. Biol. 109:73-80.
16. Swanson, S. J., Ferbas, J., Mayeux, P., and Casadevall, N. 2004. Evaluations of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron. Clin. Practice 96:c88-c95.
17. Thistlethwaite, J. R., Stuart, J. K., Mayes, J. T., Gaber, A. O., Woodle, S., Buckingham, M. R., and Stuart, F. P. 1988. Complications and monitoring of OKT3 therapy. Am. J. Kidney Dis. 11:112-119.